JAB-21822

The global KRAS inhibitors market has experienced over 400% growth since the first approval in 2021, with four drugs now authorized for treating cancers with KRAS mutations.

Jacobio Pharma's glecirasib shows significant efficacy in treating KRAS G12C-mutated non-small cell lung cancer (NSCLC) in a pivotal Phase II trial.

A phase 2b trial investigates the efficacy of Glecirasib in treating KRAS G12C-mutated non-small-cell lung cancer, involving multiple institutions across China and the USA.

DATROWAY, a TROP2-directed antibody drug conjugate (ADC), has been approved in the European Union for treating adult patients with unresectable or metastatic HR+/HER2- breast cancer who have received endocrine therapy and at least one line of chemotherapy.

Jacobio Pharma's glecirasib, a KRAS G12C inhibitor, has been granted orphan drug designation by the European Medicines Agency (EMA) for pancreatic cancer.